https://www.selleckchem.com/pr....oducts/pirtobrutinib
The model predicted that the KSQ mAb can be dosed over a less frequent regimen or at lower dose levels than the current monalizumab clinical dosing regimen of 10 mg/kg q2w. Either dosing strategy represents a competitive advantage over the current therapy. The results of this study demonstrate a key role for mechanistic modeling in identifying optimal drug parameters to inform and accelerate progression of mAb to clinical trials. Clinical significance of endometrial and peripheral blood natural killer (NK) and regulatory
Like
Comment
Share
